Kyowa Kirin & Ultragenyx: Strategic Moves to Dominate AML & Gene‑Therapy MarketsKyowa Kirin expands ziftomenib combos to boost AML market access, while Ultragenyx cuts costs and monetizes gene‑therapy assets for long‑term growth.KYOWA KIRIN CO LTD Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated Lisa Martinez 06/11/2026, 02:54 6 minutes to read
Kyowa Kirin Drives 50% Profit Surge in FY2026 First 9 Months with Biologics GrowthKyowa Kirin’s first‑nine‑month fiscal 2026 results show a 50% profit jump driven by oncology sales, reduced R&D spending and new licensing income – a profitable, growth‑oriented outlook.KYOWA KIRIN CO LTD Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated Dr. Michael Chen 04/11/2026, 14:24 4 minutes to read